Stockscreener 앱 받기
2.74
7.03%
0.18
전일 마감가:
$2.56
열려 있는:
$2.6
하루 거래량:
401.84K
Relative Volume:
1.44
시가총액:
$122.53M
수익:
-
순이익/손실:
$-27.66M
주가수익비율:
-2.8842
EPS:
-0.95
순현금흐름:
$-24.36M
1주 성능:
-2.14%
1개월 성능:
-33.17%
6개월 성능:
-10.46%
1년 성능:
+10.48%
1일 변동 폭
$2.548
$2.80
1주일 범위
$2.515
$2.84
52주 변동 폭
$1.9875
$8.535
Genelux Corp Stock (GNLX) Company Profile
명칭
Genelux Corp
전화
805-267-9889
주소
2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE
GNLX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GNLX
Genelux Corp
|
2.74 | 114.48M | 0 | -27.66M | -24.36M | -0.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Genelux Corp Stock (GNLX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-21 | 개시 | Lake Street | Buy |
| 2024-10-29 | 개시 | Guggenheim | Buy |
| 2024-08-28 | 개시 | ROTH MKM | Buy |
| 2023-11-27 | 개시 | H.C. Wainwright | Buy |
| 2023-09-12 | 개시 | Maxim Group | Buy |
| 2023-02-15 | 개시 | The Benchmark Company | Speculative Buy |
모두보기
Genelux Corp 주식(GNLX)의 최신 뉴스
Brokers Offer Predictions for Genelux Q1 Earnings - Defense World
Aug Sectors: Will Genelux Corporation benefit from AI trendsExit Point & High Yield Stock Recommendations - baoquankhu1.vn
Aug Momentum: Will Genelux Corporation benefit from AI trendsRate Hike & Smart Money Movement Tracker - baoquankhu1.vn
Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners - Yahoo Finance
Can Genelux Corporation stock sustain revenue growth2025 Earnings Surprises & AI Powered Trade Plan Recommendations - Улправда
Genelux Announces Underwritten Public Offering to Raise Capital - TipRanks
Genelux Corp Announces $20 Million Public Offering - TradingView — Track All Markets
Genelux Corporation announces pricing of $20.0 million underwritten public offering of common stock - MarketScreener
Genelux prices public offering of 6.67 million shares at $3 each - Investing.com Australia
Genelux prices public offering of 6.67 million shares at $3 each By Investing.com - Investing.com South Africa
Genelux Corporation Announces Pricing of $20 Million Public Offering of Common Stock - Quiver Quantitative
Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock - Yahoo Finance
The Great Thaw: Biotech Fundraising Surges as Monte Rosa and Genelux Tap Reopening Markets - FinancialContent
Genelux stock falls after announcing proposed public offering By Investing.com - Investing.com Nigeria
Genelux stock falls after announcing proposed public offering - Investing.com
Genelux announces proposed public offering of common stock - Investing.com
Genelux Corporation Announces Proposed Public Offering of Common Stock - MarketScreener
Cancer-focused biotech Genelux plans new public stock sale to investors - Stock Titan
Multiple Insiders Sold Genelux Shares Presenting Weak Signs For Investors - simplywall.st
Genelux reports interim data of systemic administration of Olvi-Vec - TipRanks
After-Hours Biotech Rally: Alumis, Genelux, Bright Minds, Context Therapeutics Post Big Gains - Nasdaq
Genelux data update indicates disease early control, says H.C. Wainwright - TipRanks
Genelux reports encouraging interim data for Olvi-Vec trials - MSN
Genelux stock maintains Buy rating at H.C. Wainwright on promising cancer trial data By Investing.com - Investing.com South Africa
Genelux stock maintains Buy rating at H.C. Wainwright on promising cancer trial data - Investing.com Canada
Maintaining Buy on Genelux: Early Olvi-Vec Data Signal Differentiated Potential in Relapsed/Refractory Lung Cancer - TipRanks
Genelux Reports Encouraging Interim Data for Olvi-Vec Trials - TipRanks
Experimental treatment shrank lung tumors up to 85% in early trial - Stock Titan
Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer - Sahm
Genelux (NASDAQ:GNLX) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Genelux appoints Jason Litten as chief medical officer By Investing.com - Investing.com Nigeria
Genelux Appoints Veteran Oncologist Jason Litten as CMO - TipRanks
Genelux appoints Jason Litten as CMO - TipRanks
Genelux Corporation Announces Change of Chief Medical Officer - marketscreener.com
Genelux appoints Jason Litten as chief medical officer - Investing.com India
Genelux Corporation Appoints Dr. Jason Litten as Chief Medical Officer to Advance Olvi-Vec Development - Quiver Quantitative
GENELUX CORP : BENCHMARK CUTS TARGET PRICE TO $23 FROM $25 - 富途牛牛
How interest rate cuts could boost Genelux Corporation stockAnalyst Upgrades & AI Alerts You Can Actually Trust - Bollywood Helpline
Flputnam Investment Management Co. Raises Holdings in Genelux Corporation $GNLX - MarketBeat
Genelux (NASDAQ:GNLX) Cut to Sell at Wall Street Zen - Defense World
Cappello, Genelux CTO, sells $14k in GNLX stock By Investing.com - Investing.com Nigeria
Genelux (NASDAQ:GNLX) CEO Thomas Zindrick Sells 4,509 Shares - MarketBeat
Genelux (NASDAQ:GNLX) CEO Thomas Zindrick Sells 12,673 Shares of Stock - MarketBeat
Genelux president sells $66k in GNLX stock By Investing.com - Investing.com India
Genelux SVP, Yu Yong, sells shares worth $16k By Investing.com - Investing.com Australia
Genelux SVP, Yu Yong, sells shares worth $16k - Investing.com
GENELUX Corp Executives Sell Shares to Cover Taxes - TradingView — Track All Markets
VP Yu Surrenders 4,192 Of Genelux Corp [GNLX] - TradingView — Track All Markets
Genelux reports Q3 EPS (21c), consensus (21c) - MSN
Genelux Corp (GNLX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Genelux Corp 주식 (GNLX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Yu Yong | SVP, Clinical Development |
Nov 17 '25 |
Sale |
5.37 |
973 |
5,224 |
145,844 |
| Zindrick Thomas | President and CEO |
Aug 21 '25 |
Sale |
3.33 |
12,673 |
42,159 |
542,940 |
| Zindrick Thomas | President and CEO |
Nov 17 '25 |
Sale |
5.37 |
4,509 |
24,211 |
538,431 |
| Cappello Joseph | Chief Technical Officer |
Aug 21 '25 |
Sale |
3.34 |
2,733 |
9,137 |
157,033 |
| Cappello Joseph | Chief Technical Officer |
Nov 17 '25 |
Sale |
5.37 |
973 |
5,224 |
156,060 |
| Smalling Ralph | Head of Regulatory |
Aug 21 '25 |
Sale |
3.36 |
1,244 |
4,177 |
69,746 |
| Smalling Ralph | Head of Regulatory |
Sep 03 '25 |
Sale |
3.36 |
580 |
1,948 |
69,166 |
| Smalling Ralph | Head of Regulatory |
Nov 17 '25 |
Sale |
5.37 |
343 |
1,842 |
68,823 |
| Smalling Ralph | Head of Regulatory |
Dec 05 '25 |
Sale |
4.69 |
165 |
774 |
68,658 |
| Thomas John | Director |
Dec 01 '25 |
Sale |
5.00 |
10,000 |
50,008 |
492,784 |
4.73%
0.92%
자본화:
|
볼륨(24시간):